Juno Therapeutics Profile

USD 0.35  0.41%

Acquisition by Anthony Evnin of 485 shares of Juno Therapeutics subject to Rule 16b-3

Juno Therapeutics Inc insider trading alert for grant of common stock by Anthony Evnin, the corporate stakeholder, on February 12, 2018. This event was filed by Juno Therapeutics Inc with SEC on 2016-10-17. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Juno Therapeutics Summary

Juno Therapeutics Inc (JUNO) is traded on NASDAQ in USA. It is located in WASHINGTON, U.S.A and employs 589 people. Juno Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 9.81 B. Juno Therapeutics Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 115.33 M outstanding shares of which 8.19 M shares are currently shorted by private and institutional investors with about 3.36 trading days to cover. currently holds about 927.53 M in cash with (201.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.18.
Check Juno Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Juno Therapeutics Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Juno Therapeutics Against Markets

Current Ratings

Juno Therapeutics 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 26% 
Equity ratings for Juno Therapeutics Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington. Juno Therapeutics operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 589 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameJuno Therapeutics Inc
CEOHans BishopAll Leadership
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
Business Address400 Dexter Avenue North
CIK Number01594864.0
Contact Number206 582 1600
CurrencyUSD - US Dollar


Juno Therapeutics Analyst Recommendations
Target PriceAdvice# of Analysts
Juno Therapeutics Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Juno Therapeutics Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Juno Therapeutics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.63March 1, 2017
Juno Therapeutics Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Juno Therapeutics Corporate Directors
Hal Barron Director, Ph.D
Richard Klausner Director, Ph.D
Mary Wilderotter Independent Director, Ph.D